RxDoctor Payments Data

Annika Illum, MD

Cardiovascular Disease · Dallas, TXNPI 1588865778

Payments from drug & device makers

$2,699in general payments, 2019–2025

Across 157 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$521
  • Amgen$362
  • Merck$266
  • Pfizer$254
  • Boehringer Ingelheim$243
  • Esperion Therapeutics, Inc.$171
  • plus $882 from 17 others

What the payments were for

  • Food & beverage$2,67899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,699 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$111,184
Medicare patients
176
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan153$221,502
EliquisApixaban134$171,327
JardianceEmpagliflozin103$143,852
XareltoRivaroxaban26$40,778
FarxigaDapagliflozin Propanediol38$40,050
Repatha SureclickEvolocumab27$33,607
Praluent PenAlirocumab32$31,489
Repatha SyringeEvolocumab20$30,533
LivaloPitavastatin Calcium11$7,755
VascepaIcosapent Ethyl11$7,203
Ezetimibe157$3,390
Colchicine35$3,020
Rosuvastatin Calcium209$2,222
Atorvastatin Calcium117$1,136
Metoprolol Succinate68$1,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$521$221,502153 claims
PfizerEliquis$254$171,327134 claims
Boehringer IngelheimJardiance$243$143,852103 claims
Johnson & JohnsonXarelto$46$40,77826 claims
AstraZenecaFarxiga$106$40,05038 claims
Kowa Pharmaceuticals America, Inc.Livalo$69$7,75511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →